Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus Lenvatinib for Anaplastic Thyroid Cancer
jRCT2080224758Phase 2Completed
- Sponsor
- National Cancer Center Hospital East
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab and lenvatinib in anaplastic thyroid cancer (ATC), sponsored by National Cancer Center Hospital East. Started Jul 2019; status: completed.
02
Drugs
nivolumablenvatinib
03
Conditions
anaplastic thyroid cancer (ATC)
Beyond the preview
Go deeper on jRCT2080224758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224758.